Disease on EC 3.5.3.18 - dimethylargininase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Lung Injury
Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury.
Adenocarcinoma
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.
Adenocarcinoma in Situ
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.
Adenocarcinoma of Lung
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.
Albuminuria
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
Alzheimer Disease
Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease.
Arthritis, Rheumatoid
Elevated dimethylarginine dimethylaminohydrolase (DDAH) activity in rheumatoid arthritis and spondyloarthritis.
Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis.
Asthma
Overexpression of dimethylarginine dimethylaminohydrolase 1 attenuates airway inflammation in a mouse model of asthma.
Atherosclerosis
Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis.
Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.
Effect of Lowering Asymmetric Dimethylarginine (ADMA) on Vascular Pathology in Atherosclerotic ApoE-Deficient Mice with Reduced Renal Mass.
Improvement of endothelial dysfunction in atherosclerotic rabbit aortas by ex vivo gene transferring of dimethylarginine dimethylaminohydrolase-2.
Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
Breast Neoplasms
MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.
Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
Bronchopulmonary Dysplasia
A single nucleotide polymorphism in the dimethylarginine dimethylaminohydrolase gene is associated with lower risk of pulmonary hypertension in bronchopulmonary dysplasia.
Carcinoma
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
Carcinoma, Hepatocellular
A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.
Carcinoma, Squamous Cell
DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
Cardiomegaly
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Cardiovascular Abnormalities
Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
Cardiovascular Diseases
Association of DDAH2 gene polymorphism with cardiovascular disease in Egyptian patients.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.
DDAH gene and cardiovascular risk.
DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.
Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.
Effect of CCL5 on dimethylarginine dimethylaminohydrolase-1 production in vascular smooth muscle cells from spontaneously hypertensive rats.
Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells.
Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.
Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development.
Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases.
Carotid Artery Thrombosis
Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Cerebral Hemorrhage
Common genetic variation in DDAH2 is associated with intracerebral hemorrhage in Chinese population: a multicenter case-control study in China.
Cerebrovascular Disorders
Asymmetric dimethylarginine and DDAH1 transcript variants in cardiovascular and cerebrovascular diseases.
Cholestasis
Lobe-specific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis.
Coronary Artery Disease
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients.
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study.
Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.
Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients.
Coronary Disease
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease.
Cushing Syndrome
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Cystic Fibrosis
Asymmetric Dimethylarginine Contributes to Airway Nitric Oxide Deficiency in Patients with Cystic Fibrosis.
Diabetes Mellitus
Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: Role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells.
Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.
Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with insulin sensitivity in experimental type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity.
Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: Role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine.
Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension.
Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes.
Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes.
Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes.
The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with insulin sensitivity in experimental type 2 diabetes mellitus.
The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study.
Diabetic Cardiomyopathies
DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats.
Diabetic Nephropathies
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
ADMA, SDMA and L-arginine/ADMA Ratio but not DDAH Genetic Polymorphisms are Reliable Predictors of Diabetic Nephropathy Progression as Identified by Competing Risk Analysis.
dimethylargininase deficiency
DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.
DDAH1 deficiency promotes intracellular oxidative stress and cell apoptosis via a miR-21-dependent pathway in mouse embryonic fibroblasts.
Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats.
Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.
Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.
Endometritis
Elevated Levels of ADMA Are Associated with Lower DDAH2 and Higher PRMT1 in LPS-Induced Endometritis Rats.
Erectile Dysfunction
DDAH1 and DDAH2 polymorphisms associate with asymmetrical dimethylarginine plasma levels in erectile dysfunction patients but not in healthy controls.
Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis.
Glaucoma
Elevation of serum asymmetrical and symmetrical dimethylarginine in patients with advanced glaucoma.
Glioma
Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.
Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis.
Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging.
Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.
Heart Failure
Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats.
Correlation of gene expression and clinical parameters identifies a set of genes reflecting LV systolic dysfunction and morphological alterations.
Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats.
Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases.
Hematologic Neoplasms
Asymmetric dimethylarginine in hematological malignancies: a preliminary study.
Hyperalgesia
The Involvement of DDAH1 in the Activation of Spinal NOS Signaling in Early Stage of Mechanical Allodynia Induced by Exposure to Ischemic Stress in Mice.
Hypercholesterolemia
Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
Hyperhomocysteinemia
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Placental NRP1 and VEGF expression in pre-eclamptic women and in a homocysteine-treated mouse model of pre-eclampsia.
Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia.
Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
[Effects and related mechanism of 5-aza-2'-deoxycytidine on endothelial function in rats with hyperhomocysteinemia].
Hyperlipidemias
Phosphorylation of Nonmuscle Myosin Light Chain Promotes Endothelial Injury in Hyperlipidemic Rats Through a Mechanism Involving Downregulation of Dimethylarginine Dimethylaminohydrolase 2.
Hypertension
Association between variation in the genes DDAH1 and DDAH2 and hypertension among Uygur, Kazakh and Han ethnic groups in China.
Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension.
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.
Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
DDAH gene and cardiovascular risk.
Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats.
Dimethylarginine dimethylaminohydrolase-1 mediates inhibitory effect of interleukin-10 on angiotensin II-induced hypertensive effects in vascular smooth muscle cells of spontaneously hypertensive rats.
Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertension.
Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/PTRF.
Mesenteric vascular remodeling in hyperhomocysteinemia.
miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia.
N-Acetylcysteine Prevents Programmed Hypertension in Male Rat Offspring Born to Suramin-Treated Mothers.
Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Neuropilin-1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II-induced hypertension.
Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension.
Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice.
Hypertension, Portal
Basal release of NO in the mesenteric artery in portal hypertension and cirrhosis: role of dimethylarginine dimethylaminohydrolase.
Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.
Hypertension, Pulmonary
A single nucleotide polymorphism in the dimethylarginine dimethylaminohydrolase gene is associated with lower risk of pulmonary hypertension in bronchopulmonary dysplasia.
Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats.
Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.
Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension.
Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.
Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia.
miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia.
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Hypertrophy, Right Ventricular
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Idiopathic Pulmonary Fibrosis
The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis.
Infarction, Middle Cerebral Artery
Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke.
Infections
Plasmodium Infection Is Associated with Impaired Hepatic Dimethylarginine Dimethylaminohydrolase Activity and Disruption of Nitric Oxide Synthase Inhibitor/Substrate Homeostasis.
Insulin Resistance
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity.
Asymmetric dimethylarginine (ADMA) is identified as a potential biomarker of insulin resistance in skeletal muscle.
ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Dimethylarginine dimethylaminohydrolase 1 protects against high fat diet induced hepatic steatosis and insulin resistance in mice.
Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.
The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with insulin sensitivity in experimental type 2 diabetes mellitus.
Kidney Diseases
The glomerular proteome in a model of chronic kidney disease.
Kidney Failure, Chronic
Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension.
Leukemia, Myeloid
Identification of a high-affinity network of secretagogin-binding proteins involved in vesicle secretion.
Liver Cirrhosis
Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy.
Liver Failure, Acute
The dimethylarginine (ADMA)/nitric oxide pathway in the brain and periphery of rats with thioacetamide-induced acute liver failure: Modulation by histidine.
Malaria
Plasmodium Infection Is Associated with Impaired Hepatic Dimethylarginine Dimethylaminohydrolase Activity and Disruption of Nitric Oxide Synthase Inhibitor/Substrate Homeostasis.
Melanoma
Developing an Irreversible Inhibitor of Human DDAH-1, an Enzyme Upregulated in Melanoma.
Muscle Spasticity
Association between cerebrospinal fluid levels of asymmetric dimethyl-L-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage.
Myocardial Infarction
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients.
Cardiomyocyte dimethylarginine dimethylaminohydrolase1 attenuates left-ventricular remodeling after acute myocardial infarction: involvement in oxidative stress and apoptosis.
Genotype/allelic combinations as potential predictors of myocardial infarction.
Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction.
Myocardial Ischemia
Repetitive ischemia increases myocardial dimethylarginine dimethylaminohydrolase 1 expression.
Neoplasm Metastasis
DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/?-catenin signaling pathway.
Neoplasms
A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.
Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.
Characterization of C-Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH-1.
DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.
DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/?-catenin signaling pathway.
Demethylbellidifolin inhibits adhesion of monocytes to endothelial cells via reduction of tumor necrosis factor alpha and endogenous nitric oxide synthase inhibitor level.
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.
Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis.
Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging.
Elevated Levels of ADMA Are Associated with Lower DDAH2 and Higher PRMT1 in LPS-Induced Endometritis Rats.
Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia.
Inhibition of DDAH1, but not DDAH2, results in apoptosis of a human trophoblast cell line in response to TRAIL.
Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid.
Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.
Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.
Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Proteomic analysis of prostate cancer metastasis-derived prostasomes.
Relationship between protective effect of xanthone on endothelial cells and endogenous nitric oxide synthase inhibitors.
Repetitive ischemia increases myocardial dimethylarginine dimethylaminohydrolase 1 expression.
Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
nitric-oxide synthase (nadph) deficiency
ADMA and the role of the genes: Lessons from genetically modified animals and human gene polymorphisms.
Non-alcoholic Fatty Liver Disease
Dimethylarginine dimethylaminohydrolase 1 protects against high fat diet induced hepatic steatosis and insulin resistance in mice.
Obesity
OS075. Endothelial-dependent vascular function is significantly impaired in obesity and restored by overexpression of DDAH1: Evidence for the role of ADMA.
Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction.
Pneumonia
Dimethylarginine dimethylaminohydrolase (DDAH) overexpression attenuates agricultural organic dust extract-induced inflammation.
Pre-Eclampsia
Altered methylation and expression patterns of genes regulating placental nitric oxide pathway in patients with severe preeclampsia.
Haplotypic association of DDAH1 with susceptibility to pre-eclampsia.
Nitric Oxide and Carbon Monoxide Production and Metabolism in Preeclampsia.
No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations.
No Compensatory Upregulation of Placental Dimethylarginine Dimethylaminohydrolase Activity in Preeclampsia.
Severely decreased activity of placental dimethylarginine dimethylaminohydrolase in pre-eclampsia.
[Relationship between changes of endogenous nitric oxide synthase inhibitor and hydrolase and initiation of pre-eclampsia]
Proteinuria
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
Pulmonary Arterial Hypertension
Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats.
Elevated pulmonary arterial pressure and altered expression of Ddah1 and Arg1 in mice lacking cavin-1/PTRF.
miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia.
Pulmonary Fibrosis
The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis.
Renal Insufficiency, Chronic
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.
Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.
Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
Sepsis
Dimethylarginine dimethylaminohydrolase 2 regulates nitric oxide synthesis and hemodynamics and determines outcome in polymicrobial sepsis.
Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity.
Pharmacological inhibition of DDAH1 improves survival, hemodynamics and organ function in experimental septic shock.
Pilot study of the association of the DDAH2 -449G polymorphism with asymmetric dimethylarginine and hemodynamic shock in pediatric sepsis.
Shock, Septic
Characterization of C-Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH-1.
Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity.
Genetic and pharmacological inhibition of dimethylarginine dimethylaminohydrolase 1 is protective in endotoxic shock.
Pharmacological inhibition of DDAH1 improves survival, hemodynamics and organ function in experimental septic shock.
Pilot study of the association of the DDAH2 -449G polymorphism with asymmetric dimethylarginine and hemodynamic shock in pediatric sepsis.
Sleep Wake Disorders
SZSJ protects against insomnia by a decrease in ADMA level and an improvement in DDAH production in sleep-deprived rats.
Stomach Neoplasms
DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/?-catenin signaling pathway.
Stomach Ulcer
The role of the DDAH-ADMA pathway in the protective effect of resveratrol analog BTM-0512 on gastric mucosal injury.
Stroke
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
Common genetic variation in DDAH2 is associated with intracerebral hemorrhage in Chinese population: a multicenter case-control study in China.
Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence.
Subarachnoid Hemorrhage
Involvement of accumulated NOS inhibitors and endothelin-1, enhanced arginase, and impaired DDAH activities in pulmonary dysfunction following subarachnoid hemorrhage in the rabbit.
Thrombosis
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.
Triple Negative Breast Neoplasms
Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
Uremia
Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
Vascular System Injuries
Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.
Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.